Moderna (MRNA)

The Post-Melanoma Melt-Up Meets Its ESMO Test — Quick Take

📅 2026-09-25 HealthcareBiotechmRNAOncologyUS

⚠️ Re-Research Trigger

Originally covered on 2026-08-20 at ~$69B market cap after the +177% single-day Phase 3 melanoma vaccine surge. Re-researched because MRNA has since (a) extended the move to ~+510% year-to-date and a fresh 52-week high, with a ~+25% gain in the last week alone on company-specific news, and (b) become the #2 US VolumeSurge name today ($3.2B turnover, +7.0%) inside the screener's dominant Healthcare sector (21 of 44 names). The next binary catalyst — detailed Phase 3 data at ESMO on Oct 24 — is now less than a month away.

Market Cap

~$80B

Revenue (TTM)

~$1.9B

P/E (Fwd)

N/M

Rev Growth (Q2)

+2% YoY

Why This Company Now

Moderna is the screener's standout again: the #2 US VolumeSurge pick on Friday 25 Sep at $194.82 (+7.0%) on $3.2B of turnover, with Healthcare the dominant sector (21 of 44 passing names). The re-rating is still being driven by the 19 Aug Phase 3 INTerpath-001 win — the first late-stage success for an individualized mRNA neoantigen therapy, in adjuvant melanoma with Merck's Keytruda — which has taken the stock from ~$25 to ~$195 (~+510% YTD, against a 52-week low of $22.28). Momentum has re-accelerated this week (+~25%) on anticipation of detailed Phase 3 data at the ESMO Presidential Symposium on 24 October in Madrid, alongside the launch narrative around the broader mRNA platform (CEO Bancel has been explicit that oncology, not COVID, is now the story) and regulatory progress on next-generation flu/RSV vaccines.

Financial Snapshot

Year	Revenue	Rev Growth	Op Margin	Net Income
2021	$18.5B	+2,200%	~72%	+$12.2B
2022	$19.3B	+4%	~49%	+$8.4B
2023	$6.85B	−64%	~−61%	−$4.7B
2024	$3.24B	−53%	~−102%	−$3.6B
2025	$1.92B	−41%	~−142%	−$2.8B
Q2 2026	$0.145B	+2%	n/m (loss)	−$0.78B

GAAP figures. The COVID franchise has collapsed from the 2021–22 peak (FY2025 revenue $1.92B, net loss ~$2.8B; Q1 2026 net loss ~$1.3B). Q2 2026 (reported 31 Jul) beat a low guidance bar at $145M revenue with the net loss narrowing to $782M from $825M a year earlier (loss/share $1.97 vs $2.13) as cost of sales fell ~22% YoY on manufacturing productivity. Cash and investments were $6.9B (from $7.5B in Q1), and management still guides to up to 10% revenue growth in 2026 with GAAP opex reductions. Notable in this report: 2026 revenue is seasonal, with the bulk falling in H2 — this quarter is not the base to annualise.

Bull vs Bear

✅ Bull Case

Platform validation, not one asset: INTerpath-001 met both recurrence-free and distant-metastasis-free survival in 1,137 resected Stage IIB–IV melanoma patients, following the Phase 2b 5-year data (49% risk reduction in recurrence/death, HR 0.51; 59% in distant metastasis, HR 0.411). Trials are running across NSCLC, bladder and renal cell carcinoma, with Merck's Keytruda as the commercial channel.
Cost discipline is showing, and the balance sheet funds the runway: the Q2 2026 net loss narrowed YoY on a ~22% fall in cost of sales, $6.9B of cash covers a pipeline that is now weighted to oncology rather than the shrinking COVID line.
Catalyst-rich flow and a crowded short side: full Phase 3 detail lands at the ESMO Presidential Symposium on 24 Oct; short interest has run at roughly 14–20% of free float (S3 Partners has called it the most-shorted S&P 500 name by % of float), which turned a +177% day into ~$4.8B of one-day mark-to-market losses for bears in August — squeeze fuel remains live into any positive data point.

🔴 Bear Case

The multiple has run far ahead of the P&L: ~$80B of market cap on ~$1.9B trailing revenue (~40x sales) with no profit in sight; the published analyst consensus target (MarketBeat: Hold, average ~$77) sits ~60% below spot, and Rothschild & Co. went public on 22 Sep calling Moderna "overvalued after the cancer-vaccine-led surge." Validity of that consensus is itself questionable — but it captures how far price has detached from modelled value.
The base business is still shrinking and the economics are unproven: FY2025 revenue fell 41%, Q2 2026 revenue was $145M, and personalized neoantigen therapy requires bespoke manufacturing per patient — the cost, turnaround and reimbursement model has never been demonstrated at commercial scale. Overall-survival data has still not been shown.
Positioning and technical risk are extreme into a binary: RSI is flagged overbought, price sits far above its EMA20/50/200, and our own screener tags MRNA with a "Distribution Risk" flag — after ~510% YTD, an ESMO disappointment (or any regulatory delay) is the kind of event that unwinds a momentum tape quickly, and the analyst community is not underwriting the current price.

Verdict

This remains a genuine platform event — the first late-stage validation of a personalized mRNA cancer vaccine — and the reason it keeps printing new highs is legitimate: real data, a real partner, a real short base, and a dated catalyst on 24 October. But the equity has now priced a commercial oncology franchise years before approval, on a revenue base that is still shrinking, against an analyst consensus ~60% lower and with the tape technically stretched. I would not underwrite this price; the honest position is to wait for the ESMO detail (and any sign of overall-survival benefit) before treating the melt-up as a thesis rather than momentum.

Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings and financial data providers. Levels and market-cap figures are as of the 25 Sep 2026 US VolumeSurge snapshot and are approximate; verify on a live tape.